Navigation Links
Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union
Date:12/16/2009

HAMBURG, Germany, December 16 /PRNewswire/ -- Eppendorf has initiated an import ban for Nanosphere, Inc.'s Verigene(R) and Verigene(R) SP systems for infringement of European patent EP 1 179 180 B2, titled "Method for the identification and/or the quantification of a target compound". The import ban covers any and all imports of the respective products into any country of the European Union. Customs authorities are required to confiscate any violating products.

The patent covers Eppendorf's Silverquant(R) microarray technology, offered in Eppendorf's Silverquant scanner and Silverquant detection kit used e.g. for Eppendorf's own microarrays. The technology is also licensed to two companies for commercialization with their microarrays.

In addition, Eppendorf has successfully initiated an import ban for the Verigene(R) kits based on the German utility model DE 20023342U1, also covering Eppendorf's Silverquant products. This ban prohibits imports into Germany either from outside the EU or from within the EU.

"Considering Nanosphere's announcement of having received the CE mark for the Verigene(R) system, Eppendorf has taken these steps to prevent the introduction of these products that are not licensed to use our patented technology into the European Union", commented Sven Bulow, Managing Director of Eppendorf Biochip Systems GmbH.

Eppendorf AG was founded in Hamburg in 1945 and has more than 2,450 employees worldwide. The company has subsidiaries in 20 countries and is represented in all other markets by distributors.

In fiscal 2008, the company's sales revenues amounted to EUR 410 million with earnings before interest and taxes (EBIT) of EUR 71.9 million.

    Contact:
    Dr. Sven Buelow
    Managing Director
    Eppendorf Biochip Systems GmbH
    Tel: +49-40-538-01-500
    Fax: +49-40-538-01-140
    buelow.s@eppendorf.de


SOURCE Eppendorf AG


'/>"/>
SOURCE Eppendorf AG
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. New Brunswick Scientific Completes Merger Transaction with Eppendorf
2. EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme
3. Life on Mars pregnancy test successfully launched
4. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
5. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
6. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
7. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
8. TopoTarget Successfully Buys Back Full Control of Belinostat
9. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
10. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
11. CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... YORK , March 24, 2017 ... ended the trading session at 5,817.69, down 0.07%; the ... at 20,656.58; and the S&P 500 closed at 2,345.96, ... as 4 sectors closed in green, 4 sectors finished ... day. This Friday, Stock-Callers.com has initiated reports coverage on ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... that exhibits both viscous and elastic characteristics when deformed, which is identical to ... properties to gently absorb compressive forces and return to its natural state along ...
(Date:3/23/2017)... 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), ... for solid tumor cancers, today announced that yesterday ... announced last Friday, March 17, 2017. ... securities totaling 28,843,692 shares, comprised of 18,843,692 common ... of Class C Warrants pre-funded at the closing ...
(Date:3/23/2017)... March 23, 2017  BioPharmX Corporation (NYSE MKT: ... the dermatology market, today reported financial results for ... and will provide an update on the company,s ... "We are pleased to report that ... BioPharmX," said President Anja Krammer. "We achieved key ...
Breaking Biology Technology:
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber Ventures ... it has led a $3.5 million investment in  Polarity ... Strategic Cyber Ventures is DC based and is led ... Hank Thomas . Ron Gula , also a ... also participated in this series A round of funding. ...
(Date:2/22/2017)... , Feb. 22, 2017 With ... 2021, ABI Research identifies four technologies that innovative ... to secure significant share in the changing competitive ... and passive authentication.   "Companies can ... comes to security," says Dimitrios Pavlakis , ...
(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
Breaking Biology News(10 mins):